<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1996">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05135182</url>
  </required_header>
  <id_info>
    <org_study_id>2021-SDU-QILU-G226</org_study_id>
    <nct_id>NCT05135182</nct_id>
  </id_info>
  <brief_title>Helicobacter Pylori Rescue Treatment in Patients Allergic to Penicillin</brief_title>
  <official_title>Helicobacter Pylori Rescue Treatment Containing Tetracycline in Patients Allergic to Penicillin:a Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess and compare the effectiveness of&#xD;
      furazolidone-tetracycline-containing and metronidazole-tetracycline-containing quadruple&#xD;
      regimens for the rescue treatment of Helicobacter pylori infection inpatients allergic to&#xD;
      penicillin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Helicobacter pylori(H.pylori), which infects about 50% of the global population,has been&#xD;
      recognized as a main risk factor of multiple gastric pathologies,especially non-cardiac&#xD;
      gastric cancer. Strongly evidence supports that H.pylori eradication is an effective approach&#xD;
      to reduce the incidence of those pathologies.However,Helicobacter pylori eradication is a&#xD;
      challenge in patients allergic to penicillin. Therefore, the investigators aim to assess and&#xD;
      compare the effectiveness of furazolidone-tetracycline-containing and&#xD;
      metronidazole-tetracycline-containing quadruple regimens for the rescue treatment of&#xD;
      Helicobacter pylori infection in patients allergic to penicillin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rates in 2 groups</measure>
    <time_frame>12 months</time_frame>
    <description>Both intention to treat(ITT) and per-protocol(PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>furazolidone-tetracycline-containing quadruple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients in furazolidone-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid, tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and furazolidone 100mg po bid for 14d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metronidazole-tetracycline-containing quadruple group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients in metronidazole-tetracycline-containing quadruple group will receive vonoprazan fumarate 20mg po bid,tetracycline 500mg po qid , bismuth potassium citrate(Lizhudele) 220mg po bid, and metronidazole 400mg po qid for 14d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furazolidone</intervention_name>
    <description>Furazolidone-tetracycline-containing quadruple regimens</description>
    <arm_group_label>furazolidone-tetracycline-containing quadruple</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>metronidazole-tetracycline-containing quadruple regimens</description>
    <arm_group_label>metronidazole-tetracycline-containing quadruple group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-70 with H. pylori infection.&#xD;
&#xD;
          -  Patients with previous Helicobacter pylori eradication.&#xD;
&#xD;
          -  Patients Allergic to Penicillin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients treated with H2-receptor antagonist, PPI, bismuth and antibiotics in the&#xD;
             previous 4 weeks.&#xD;
&#xD;
          -  Patients with gastrectomy, acute GI bleeding and advanced gastric cancer.&#xD;
&#xD;
          -  Patients with known or suspected allergy to study medications.&#xD;
&#xD;
          -  Currently pregnant or lactating.&#xD;
&#xD;
          -  Inability to provide informed consent and other situations that could interfere with&#xD;
             the examination or therapeutic protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiuli Zuo</last_name>
    <phone>15588818685</phone>
    <email>zuoxiuli@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu hosipital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 23, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 26, 2021</study_first_posted>
  <last_update_submitted>November 28, 2021</last_update_submitted>
  <last_update_submitted_qc>November 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>Professor, Director of gastroenterology department of Qilu hospital</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Eradication</keyword>
  <keyword>Allergic</keyword>
  <keyword>Penicillin</keyword>
  <keyword>Tetracycline</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Furazolidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

